Product Name | Midostaurin |
Description |
Kinase inhibitor |
Purity | >98% (TLC) |
CAS No. | 120685-11-2 |
Molecular Formula | C35H30N4O4 |
Molecular Weight | 570.6 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml) or 100% ethanol (2.5 mg/ml) |
Source | Synthetic |
Appearance | White to off-white powder |
SMILES | [N]48C1=C(C7=C(C2=C1[N](C3=CC=CC=C23)[C@@H]5O[C@]4([C@@]([C@@H]5N(C)C(=O)C6=CC=CC=C6)(OC)C)C)C(NC7)=O)C9=C8C=CC=C9 |
InChI | InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,( |
InChIKey | BMGQWWVMWDBQGC-PZFYLCKJSA-N |
Safety Phrases |
Classification: Not a hazardous substance or mixture. Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
Cite This Product | Midostaurin (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-468) |
Alternative Names | 4'-N-Benzoyl-staurosporine, PKC-412, CGP 41251 |
Research Areas | Apoptosis, Cancer, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors |
PubChem ID | 24202429 |
Scientific Background | Midostaurin is a broad-spectrum protein kinase inhibitor with activity against PKC isoforms (α, β, γ), Flk, and c-Kit. In neurodegenerative disease research, Midostaurin is used to investigate the role of PKC and related kinases in neuronal signaling, apoptosis, and inflammation. Its ability to induce apoptosis and inhibit proliferative signaling pathways makes it a valuable tool for studying neurodegeneration, particularly in models involving aberrant kinase activity and glial activation. |
References |
1. Fabbro D., et al. (2000) Anti-Cancer Drug Design. 15(1): 17–28. 2. Odgerel, T., et al. (2008) Oncogene. 27(22): 3102–3110. 3. Bahlis, N.J., et al. (2005) Leukemia & Lymphoma. 46(6): 899–908. |
Reviews
There are no reviews yet.